Systematic Review of Immunosuppressant Guidelines in the COVID-19 Pandemic

Fenella Barlow-Pay, Thura Win Htut, Mina Khezrian, Phyo K Myint

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Individuals taking immunosuppressants are at increased susceptibility to viral infections in general. However, due to the novel nature of the COVID-19, there is a lack of evidence about the specific risks of the disease in this patient group. This systematic review aims to summarize the current international clinical guidelines to highlight areas where research is needed through critical appraisal of evidence base of these guidelines.
Design and Methods: We conducted a systematic review of clinical practice guidelines about the usage of immunosuppressant during the COVID-19 pandemic. Electronic databases including MEDLINE and the websites of relevant professional bodies were searched for English language guidelines that were published or updated between March 2020 and May 2020 in this area. We assessed the quality and consistency of guidelines. The evidence base underpinning these guidelines was critically appraised using GRADE criteria.
Results: Twenty-three guidelines were included. Most guidelines (n=15, 65.2%) informed and updated evidence based on expert opinion. The methodological quality of the guidelines varied, ranging from “very low” to “moderate”. Guidelines consistently recommended that high risk patients, including those who are taking high doses of steroids for more than a month, or a combination of two or more immunosuppressant, should be shielding during the outbreak. Most guidelines stated that steroids usage should not be stopped abruptly and advised on individualised risk-benefit analysis considering the risk of the effect of COVID-19 infection and the relapse of the autoimmune condition in patients.
Discussion: Clinical practice guidelines on taking immunosuppressant during the COVID-19 outbreak, vary in quality. The level of evidence informing the available guidelines was generally low. Given the novel nature of COVID-19, the guidelines draw on existing knowledge and data refer to the use of immunosuppressants and risks of serious infections of other aetiologies and have extrapolated these to form their evidence base.
Original languageEnglish
JournalTherapeutic Advances in Drug Safety
Publication statusAccepted/In press - 9 Dec 2020

Keywords

  • Immunosuppression
  • COVID-19
  • Clinical guidelines

Fingerprint Dive into the research topics of 'Systematic Review of Immunosuppressant Guidelines in the COVID-19 Pandemic'. Together they form a unique fingerprint.

Cite this